uproleselan
Small moleculeexperimental
Clinical trial activity
17 trials · 14 clinical orgs · 0 marketing orgs
Phase 1
13
Phase 2
8
Phase 3
3
Phase 4
0
Earliest trial started Jun 1, 2014 (NCT02168595)
Timeline
Indications
Mechanism of action
- Selectin EANTAGONIST
Selectin E antagonist
- SelectinINHIBITOR
Selectin inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC[C@H]1C[C@@H](C(=O)NCCNC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOC)C[C@@H](O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O[C@@H](CC3CCCCC3)C(=O)O)[C@H]2NC(C)=O)[C@@H]1O[C@@H]1O[C@@H](C)[C@@H](O)[C@@H](O)[C@@H]1O- Mol. weight
- 1304.53 g/mol
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3989971 ↗
Also known as
- gmi-1271
- gmi-1271
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05569512 | Phase 1/Phase 2 (Phase 2) | Oct 6, 2022 | GlycoMimetics, Inc., Harvard University |
| NCT05146739 | Phase 1 | Jun 28, 2022 | National Cancer Institute (NCI) |
| NCT05057221 | Phase 1/Phase 2 (Phase 2) | Nov 30, 2021 | GlycoMimetics, Inc., University of Michigan |
| NCT05054543 | Phase 3 | Oct 18, 2021 | Apollomics, Inc., Chinese Academy of Medical Sciences, Zhejiang CrownMab Biotech Co. Ltd |
| NCT04964505 | Phase 1 | Jul 2, 2021 | GlycoMimetics, Inc., National Cancer Institute (NCI), University of California, Davis |
| NCT04848974 | Phase 1/Phase 2 (Phase 2) | Jun 11, 2021 | University of Texas at Houston |
| NCT04682405 | Phase 2 | Mar 31, 2021 | GlycoMimetics, Inc., Washington University in St. Louis |
| NCT04839341 | Phase 1 | Feb 24, 2021 | Apollomics, Inc., Sheffield Hallam University, Zhejiang CrownMab Biotech Co. Ltd |
| NCT03701308 | Phase 2/Phase 3 (Phase 3) | Jan 16, 2019 | National Cancer Institute (NCI) |
| NCT03616470 | Phase 3 | Sep 30, 2018 | GlycoMimetics, Inc., Harvard University |
| NCT03606447 | Phase 1 | Aug 31, 2018 | GlycoMimetics, Inc., Quotient |
| NCT02744833 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2016 | GlycoMimetics, Inc., University of Michigan |
| NCT02811822 | Phase 1 | Jun 1, 2016 | GlycoMimetics, Inc., National University of Ireland |
| NCT02703051 | Phase 1 | Nov 1, 2015 | Celerion, GlycoMimetics, Inc. |
| NCT02306291 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2015 | GlycoMimetics, Inc., Harvard University |
| NCT02271113 | Phase 1 | Oct 1, 2014 | GlycoMimetics, Inc., University of Michigan |
| NCT02168595 | Phase 1 | Jun 1, 2014 | Celerion, GlycoMimetics, Inc. |
Showing 17 of 17 trials
Page 1 / 1
Organizations
Research & Development (14)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlycoMimetics, Inc. | For profit | 12 | 8 | 3 | 2014 |
| Harvard University | Academic/Hospital | 3 | 1 | 2 | 2015 |
| National Cancer Institute (NCI) | Government | 3 | 2 | 2 | 2019 |
| University of Michigan | Academic/Hospital | 3 | 1 | 2 | 2014 |
| Apollomics, Inc. | For profit | 2 | 2 | 2 | 2021 |
| Celerion | For profit | 2 | 0 | 1 | 2014 |
| Zhejiang CrownMab Biotech Co. Ltd | For profit | 2 | 0 | 2 | 2021 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2021 |
| National University of Ireland | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Quotient | For profit | 1 | 0 | 1 | 2018 |
| Sheffield Hallam University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| University of California, Davis | Academic/Hospital | 1 | 1 | 1 | 2021 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Washington University in St. Louis | Academic/Hospital | 1 | 1 | 1 | 2021 |
14 organizations
Page 1 / 1